![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Poor ADE Procedures Lead to Warning Letter for Elite Laboratories
Poor ADE Procedures Lead to Warning Letter for Elite Laboratories
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/GuiltyStamp.gif?t=1475621523&width=430)
Elite Laboratories has been given a warning letter due to a failure to develop adequate written procedures, particularly for adverse drug experiences (ADEs).
The FDA performed an inspection of Elite’s facility in Northvale, New Jersey, between Jan. 5 and Feb. 2.
According to the letter, Elite’s Standard Operating Procedures (SOPs) fail to address how the company receives and monitors ADE information from foreign and domestic sources.
Upcoming Events
-
21Oct